Status:

TERMINATED

Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

Lead Sponsor:

National Eye Institute (NEI)

Conditions:

Diabetic Retinopathy

Diabetic Macular Edema

Eligibility:

All Genders

18+ years

Brief Summary

Background: \- Diabetic macular edema (DME) is a common condition in people with diabetes. DME occurs when blood vessels in the eye leak fluid, resulting in swelling inside the back of the eye and pr...

Detailed Description

Objective: The objective of this study is to test the hypothesis that genetic polymorphisms of vascular endothelial growth factor (VEGF), erythropoietin (EPO), endothelin-1 (EDN1) and receptor for ad...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • All participants must meet the following criteria:
  • Participant is diagnosed with type 2 diabetes prior to enrollment.
  • Participant must understand and sign this protocol s informed consent document and agree to provide a blood sample for analysis.
  • Participant must be 18 years of age or older.\<TAB\>
  • DME Participants (cases):
  • Participant is diagnosed with active DME defined by fluorescein leakage associated with either central retinal thickness greater than 260 microns on spectral domain OCT or cystic changes present on OCT.
  • OR
  • Participant has evidence of focal laser scars indicative of prior DME Investigators will verify the laser therapy was performed for DME via medical records, fluorescein angiograms or photographs.
  • Non-DME Participants (controls)
  • Participant has no evidence of DME defined fluorescein leakage associated with either central retinal thickness greater than 260 microns on spectral domain OCT or cystic changes present on OCT.
  • Participant has no evidence of focal laser scars indicative of prior DME.
  • EXCLUSION CRITERIA:
  • Participant has another retinal disease that may confound the evaluation of the DME. Examples include vein occlusions, uveitic macular edema or neovascular age-related macular degeneration.
  • Participant has opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate dilated examination.

Exclusion

    Key Trial Info

    Start Date :

    July 7 2010

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 7 2013

    Estimated Enrollment :

    68 Patients enrolled

    Trial Details

    Trial ID

    NCT01168258

    Start Date

    July 7 2010

    End Date

    August 7 2013

    Last Update

    October 6 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892